Breast cancer survival in the US and Europe: A CONCORD high-resolution study

Claudia Allemani, Milena Sant, Hannah K. Weir, Lisa C. Richardson, Paolo Baili, Hans Storm, Sabine Siesling, Ana Torrella-Ramos, Adri C. Voogd, Tiiu Aareleid, Eva Ardanaz, Franco Berrino, Magdalena Bielska-Lasota, Susan Bolick, Claudia Cirilli, Marc Colonna, Paolo Contiero, Rosemary D Cress, Emanuele Crocetti, John P. FultonPascale Grosclaude, Timo Hakulinen, M. Isabel Izarzugaza, Per Malmström, Karin Peignaux, Maja Primic-Žakelj, Jadwiga Rachtan, Chakameh Safaei Diba, Maria José Sánchez, Maria J. Schymura, Tiefu Shen, Adele Traina, Laufey Tryggvadottir, Rosario Tumino, Michel Velten, Marina Vercelli, Holly J. Wolf, Anne Sophie Woronoff, Xiaocheng Wu, Michel P. Coleman

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Abstract

Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39%) than in Europe (32%), while locally advanced tumors were twice as frequent in Europe (8%), and metastatic tumors of similar frequency (5-6%). Net survival in Northern, Western and Southern Europe (81-84%) was similar to that in the US (84%), but lower in Eastern Europe (69%). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment.

Original languageEnglish (US)
Pages (from-to)1170-1181
Number of pages12
JournalInternational Journal of Cancer
Volume132
Issue number5
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Keywords

  • cancer registries
  • CONCORD
  • excess hazard
  • net survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Breast cancer survival in the US and Europe: A CONCORD high-resolution study'. Together they form a unique fingerprint.

Cite this